Senate’s US FDA User Fee Bill Answers Biosimilar Interchangeable Exclusivity Questions

The bill would allow for tentative interchangeable approvals, as well as shared first interchangeable exclusivity for multiple first filers.

biologic
The Senate bill would address some biosimilar questions, but others still linger. • Source: Shutterstock

Biosimilar sponsors would gain a tentative approval pathway and shared exclusivity for interchangeable products in the Senate version of the US Food and Drug Administration user fee reauthorization bill, answers to long-pondered questions about the products’ regulation.

The bill, released on 17 May, would rewrite a section of the biosimilar law to state that the FDA...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Biosimilars

More from Biosimilars & Generics